Comparative Pharmacology
Head-to-head clinical analysis: ASTRAMORPH PF versus DOLENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTRAMORPH PF versus DOLENE.
ASTRAMORPH PF vs DOLENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Category C
Category C
Opioid Analgesic
Opioid Analgesic